Nektar Therapeutics
NKTR
$0.7955
$0.05487.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.26M | -37.06M | -52.36M | -36.80M | -42.08M |
| Total Depreciation and Amortization | 332.00K | 993.00K | 1.46M | 1.61M | 1.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -42.27M | -8.96M | 2.40M | -6.07M | -1.75M |
| Change in Net Operating Assets | -11.52M | 1.09M | 10.80M | -6.62M | -4.87M |
| Cash from Operations | -46.19M | -43.93M | -37.70M | -47.89M | -47.05M |
| Capital Expenditure | -459.00K | -666.00K | -186.00K | -157.00K | -237.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 65.39M | -- | -- | -- | -- |
| Other Investing Activities | -4.71M | 46.78M | 17.17M | 19.42M | 17.62M |
| Cash from Investing | 60.21M | 46.12M | 16.98M | 19.26M | 17.38M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 83.00K | 13.00K | 19.00K | 3.00K | 12.00K |
| Repurchase of Common Stock | 0.00 | -3.00M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 3.00M | 0.00 | 42.00M | -- |
| Cash from Financing | 83.00K | 13.00K | 19.00K | 42.00M | 12.00K |
| Foreign Exchange rate Adjustments | 33.00K | -28.00K | -1.00K | -8.00K | 8.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.14M | 2.17M | -20.70M | 13.37M | -29.64M |